MBX 2109, A Once-Weekly Parathyroid Hormone Replacement Therapy Prodrug: Phase 1, First-In-Human, Randomized Trial
The sustained-action PTH prodrug MBX 2109 was well tolerated with no unexpected, off-target safety issues. The long half-life and flat exposure profile of MBX 2109's biologically active PTH agonist supports once-weekly administration. MBX 2109 doses were identified for future studies.
Authors
- Patricia I. Carney (ORCID: https://orcid.org/0009-0009-3946-2740)
- Kristi Schneider
- Richard D. DiMarchi (ORCID: https://orcid.org/0000-0003-0220-4085)
- F. Zhang (ORCID: https://orcid.org/0009-0007-1854-6393)
- Gordon B. Cutler (ORCID: https://orcid.org/0000-0001-8925-5728)
Institutions
- Delta Air Lines (United States) (US)
- Gordon State College (US)
- Indiana University Bloomington (US)
Publication Details
- Journal
- The Journal of Clinical Endocrinology & Metabolism
- Published
- 2024-11-22
- DOI
- https://doi.org/10.1210/clinem/dgae808
- Citations
- 10
- Primary Topic
- Parathyroid Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.39